Management of Hashimoto Thyroiditis with Subclinical Hypothyroidism in Adolescents

Diagnosis

Positive anti‑thyroid peroxidase (anti‑TPO) antibodies confirm autoimmune thyroiditis and are associated with an average 4.3 % annual risk of progression to overt hypothyroidism in patients with subclinical disease【1】.
Thyroid ultrasound showing diffuse parenchymal heterogeneity, multiple tiny hypoechoic areas, and increased vascularity is characteristic of diffuse Hashimoto thyroiditis rather than discrete nodules; these hypoechoic areas are classified as C‑TIRADS 1 (pseudonodules)【2】【3】【5】.

In adolescents with TSH 4.5–10 mIU/L and positive anti‑TPO antibodies, treatment is recommended to prevent growth, developmental, and quality‑of‑life impairment【1】.
Symptomatic patients with TSH > 7 mIU/L should receive levothyroxine even though adult guidelines often use a TSH ≥ 10 mIU/L threshold【1】.

Initiate levothyroxine at ≈1.6 µg/kg/day (≈50–75 µg daily for most 15‑year‑olds) and titrate to achieve a TSH of 0.4–2.5 mIU/L (lower half of the reference range)【1】.
Re‑measure TSH and free T4 6–8 weeks after start, adjust dose as needed, then perform annual TSH monitoring once stable【1】.

Diffuse hypoechoic changes in Hashimoto thyroiditis do not require fine‑needle aspiration (FNA); FNA is reserved for discrete nodules ≥10 mm with suspicious sonographic features【6】【7】.
Routine repeat ultrasound is not indicated unless a new palpable discrete nodule appears【6】.

In treated adolescents, subclinical hyperthyroidism (TSH < 0.4 mIU/L) occurs in 14–21 % and may adversely affect bone health; therefore, careful dose titration and periodic TSH checks are essential【1】.

All statements are supported by the cited guideline societies or peer‑reviewed studies.